Genetic Signatures Ltd
ASX:GSS

Watchlist Manager
Genetic Signatures Ltd Logo
Genetic Signatures Ltd
ASX:GSS
Watchlist
Price: 0.235 AUD -2.08%
Market Cap: 53.4m AUD

Genetic Signatures Ltd
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Genetic Signatures Ltd
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Genetic Signatures Ltd
ASX:GSS
Stock-Based Compensation
AU$740k
CAGR 3-Years
-27%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Genetic Technologies Ltd
ASX:GTG
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Proteomics International Laboratories Ltd
ASX:PIQ
Stock-Based Compensation
AU$773.2k
CAGR 3-Years
15%
CAGR 5-Years
47%
CAGR 10-Years
N/A
T
Trajan Group Holdings Ltd
ASX:TRJ
Stock-Based Compensation
AU$602k
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cryosite Ltd
ASX:CTE
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
EZZ Life Science Holdings Ltd
ASX:EZZ
Stock-Based Compensation
AU$1.9m
CAGR 3-Years
129%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genetic Signatures Ltd
Glance View

Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.

GSS Intrinsic Value
0.769 AUD
Undervaluation 69%
Intrinsic Value
Price

See Also

What is Genetic Signatures Ltd's Stock-Based Compensation?
Stock-Based Compensation
740k AUD

Based on the financial report for Jun 30, 2025, Genetic Signatures Ltd's Stock-Based Compensation amounts to 740k AUD.

What is Genetic Signatures Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
5%

Over the last year, the Stock-Based Compensation growth was -18%. The average annual Stock-Based Compensation growth rates for Genetic Signatures Ltd have been -27% over the past three years , 5% over the past five years .

Back to Top